Streetbeat News

Revenues

PTLO

Portillo's, a fast-casual restaurant chain, is expanding rapidly despite declining comparable sales. The company aims to grow from 90 to 920 locations, focusing on the Sunbelt region. The stock has dropped 40.3% YTD, presenting a potential buying opportunity under $10, with an upside to $12.

Portfolio Pulse from

December 16, 2024 | 8:30 am

TSLA

Tesla's stock has surged significantly post-2024 election, driven by Elon Musk's ties with Trump and potential deregulation benefits. Favorable regulatory changes and growth in China could boost Tesla's market performance in 2025, with forecasted delivery growth and strong margins supporting continued momentum.

Portfolio Pulse from

December 16, 2024 | 8:30 am

RBWRF

Rainbow Rare Earths Ltd announced that a new study of the Phalaborwa project in South Africa confirms its exceptional economic potential, with high margins and increased economic confidence compared to the initial PEA.

Portfolio Pulse from

December 16, 2024 | 8:00 am

NU

Nu Holdings, known for its rapid growth and low customer acquisition costs, is poised to become a superapp in Latin America. With 110 million customers, its expansion into Mexico and potential entry into Argentina offer significant revenue growth opportunities despite economic and geopolitical risks.

Portfolio Pulse from

December 16, 2024 | 7:15 am

RVTY

Revvity, Inc. is a leader in life sciences and diagnostics with a strong recurring revenue base, making it a low-risk biopharma investment. The company has a global presence and a significant market opportunity with an estimated TAM over $60 billion.

Portfolio Pulse from

December 16, 2024 | 5:45 am

MRK

Merck's shares have declined, increasing its dividend yield and compressing its valuation, making it an attractive investment opportunity. Keytruda shows strong revenue growth with potential for further approvals. Merck's diverse drug portfolio and robust pipeline support future growth.

Portfolio Pulse from

December 16, 2024 | 5:45 am

IBRX

ImmunityBio conducted a $100M public offering to support ANKTIVA's commercialization, despite concerns about dilution and financial health. The company's cash burn rate is a concern, but ANKTIVA's performance and future milestones could drive growth. Multiple offerings may be needed before profitability, but potential revenue growth by 2029 supports a bullish outlook.

Portfolio Pulse from

December 16, 2024 | 5:45 am

CIO

City Office REIT (CIO) is trading at a low valuation with a high free cash flow yield. Despite its debt, CIO's free cash flow covers its dividends, offering attractive yields. The company's occupancy rate is expected to increase, supported by strong leasing momentum.

Portfolio Pulse from

December 16, 2024 | 5:15 am

CCL

CRUZ

Carnival Corporation is recommended as a buy due to strong earnings, record customer deposits, and positive growth prospects, despite some valuation concerns and macro risks. The CRUZ ETF has outperformed the S&P 500, driven by high travel demand.

Portfolio Pulse from

December 16, 2024 | 5:15 am

RITM

Rithm Capital offers a stable 9% yield with a strong dividend coverage ratio of 2.2x, supported by a diversified revenue stream and recent acquisitions.

Portfolio Pulse from

December 16, 2024 | 4:15 am